SCCM Resource Library-Novel Therapies for Sepsis

Video Transcription

Video Summary

The speaker discussed the exploration of immune restorative and anti-inflammatory therapies for sepsis, outlining current knowledge and challenges in this field. They identified molecular targets and pathways in clinical trials, including interferon gamma, IL-7, the TY-2 angiopoietin pathway, and cell-free hemoglobin. Interferon gamma's dual role in sepsis prompted debates, with trials ongoing to assess its impacts. IL-7's potential in boosting lymphocyte counts faced setbacks due to safety issues. Focus on endothelial pathways highlighted angiopoietin 2's relevance, though trials remain limited. Cell-free hemoglobin's role in endothelial injury was explored, with a notable trial examining acetaminophen as a potential therapy. The speaker also emphasized the importance of machine learning and rapid biomarker assays for patient classification and treatment optimization. They highlighted the necessity of novel trial designs, as seen during COVID-19, to advance sepsis research rapidly and effectively utilize human specimens and AI technologies.

Asset Caption

One-Hour Concurrent Session | New Immune Targets in Sepsis

Meta Tag

Content Type Presentation

Membership Level Professional

Membership Level Select

Year 2024

Keywords

sepsis therapies

immune restoration

molecular targets

machine learning

novel trial designs

	Society of Critical Care Medicine 500 Midway Drive Mount Prospect, IL 60056 USA Phone: +1 847 827-6888 Fax: +1 847 439-7226 Email: support@sccm.org	Contact Us About SCCM Newsroom Advertising & Sponsorship DONATE	MySCCM LearnICU Patients & Families Surviving Sepsis Campaign Critical Care Societies Collaborative	GET OUR NEWSLETTER
© Society of Critical Care Medicine. All rights reserved. \| Privacy Statement \| Terms & Conditions The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.